GLI1 and melanoma: Treatment of melanoma cells with AKT1 inhibitors decreased the number of cells with nuclear Gli1 labeling, while increasing the number of cells with cytoplasmic Gli1 labeling, suggesting that AKT1 may be required for Gli1 nuclear localization and transcriptional activity [81].